ISIN:DE0006632003

EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer

Retrieved on: 
Donnerstag, März 16, 2023
Research, FSE, Corporate communication, J. P. Morgan, Jefferies, Neil Woodford, University College London, Financial Oversight and Management Board for Puerto Rico, Patient, Ta Sung Lee, Goldman Sachs, Strategic management, Security (finance), Management, Physiology, Pharmacology, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding Sung Lee.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding Sung Lee.
  • “I am pleased to welcome Lucinda to MorphoSys as our new Chief Financial Officer,” said Marc Cluzel, M.D., Ph.D., Chairman of the MorphoSys Supervisory Board.
  • “Lucinda will bring a strong skill set to MorphoSys with her broad biotech experience in corporate roles, as an analyst and investment professional, and the impact she has made in leading finance, strategy and investor relations divisions.”
    Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, added: “Lucinda has achieved tremendous success in designing and executing financial and business transactions.
  • “MorphoSys has successfully honed its focus on oncology and has a strong cash position to execute on their great opportunities.”
    Lucinda Crabtree joins MorphoSys from Autolus Therapeutics, a clinical-stage biopharmaceutical company developing T cell therapies, where she most recently served as Chief Financial Officer.

EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, März 16, 2023
Constellation, Progression-free survival, Cancer, Research, Conference, FSE, Workforce, Lenalidomide, DLBCL, Webcast, Significant event audit, Lymphoma, Saskatchewan River Sturgeon Management Board, Tafasitamab, Patient, ASH, JAK, Safety, Conference call, Doctor of Philosophy, Cryptocurrency, Video game, Pharmaceutical industry, Ruxolitinib, Novartis, MorphoSys

MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.

Key Points: 
  • MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
  • Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the fourth quarter  2022 and € 3.0 million for the full year of 2022.
  • Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
  • This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023

Retrieved on: 
Samstag, März 11, 2023
EDT, Webcast, Conference, Management, CET, Q&A, MorphoSys, GMT, FSE, Cryptocurrency, Video game

Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023

Key Points: 
  • Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
  • MorphoSys' Management team will host a conference call and webcast on March 16, 2023 at 01:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present the results for the financial year 2022 and provide an outlook for 2023.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.

EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

Retrieved on: 
Donnerstag, März 2, 2023
Research, Cancer, FSE, Investment, Workforce, Science, Patient, MorphoSys, Pharmaceutical industry, Ruxolitinib

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.
  • While the data from these pre-clinical programs are promising, MorphoSys would need to make substantial investments to bring these programs into the clinic.
  • As a result, MorphoSys will reduce its workforce at the company’s headquarters in Planegg, Germany, by approximately 17%.
  • The company will focus its remaining research work on translational research and technical development support for its mid- to late-stage clinical programs.

EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Retrieved on: 
Sonntag, Januar 22, 2023
SG, FSE, Patient, Medicine, NCCN, B-cell lymphoma, Royalty Pharma, Life insurance, Security (finance), Bank, Assurance services, Bookkeeping, Clothing, Music, Tafasitamab, Incyte, MorphoSys

MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Key Points: 
  • MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) today reported preliminary Monjuvi® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023.
  • Preliminary Monjuvi (tafasitamab-cxix) U.S. net product sales are US$ 25.3 million (€ 24.0 million) for the fourth quarter and US$ 89.4 million (€ 84.9 million) for the full year of 2022.
  • For the full year of 2023, MorphoSys expects Monjuvi U.S. net product sales in the range of US$ 80 to 95 million.